01 — At a Glance
The World’s Quietest Chemical Superpower Just Got Louder
- 52-Week High / Low₹2,040 / ₹1,324
- Q3 FY26 Revenue₹529 Cr
- Q3 FY26 PAT₹108 Cr
- TTM EPS₹46.10
- Annualised EPS (Q3 Avg × 4)₹45.05
- Book Value / Share₹287
- Price to Book4.83x
- OPM (Q3 FY26)30.4%
- Debt / Equity0.00x
- Exports % (FY24)55%
Flash Summary: Vinati Organics delivered Q3 FY26 revenue of ₹529 Cr (+1.34% YoY), PAT ₹108 Cr (+12.5% YoY) and OPM of 30.4%. ATBS Phase-1 capacity addition of 10,000 TPA commenced commercial operations on 5 Nov 2025. ₹570 Cr capex pipeline for new molecules. Stock at ₹1,386, down 11% in a year, still trades at 30.1x TTM EPS while holding 65% global share in two blockbuster products. The market is clearly asleep at the wheel.
02 — Introduction
The Chemical Company That Owns Two Global Markets And Still Gets Ignored
Picture this: you are the world’s largest producer of two hyper-specialty molecules that go into everything from pharmaceuticals to water treatment polymers. You have 65% global market share in both. You run zero long-term debt. You generate ₹494 Cr operating cash flow last year. And yet your stock is down 11% in the last twelve months. Welcome to Vinati Organics — the classic “too boring to tweet, too profitable to ignore” Indian specialty chemical story.
Incorporated in 1989, this Maharashtra-based outfit makes over 30 products across specialty aromatics, monomers, butyl phenols, antioxidants and polymers. IBB and ATBS alone contributed 49% of revenue in FY24 and still dominate. Exports are 55%, serving 40 countries with long-term contracts to BASF, SNF, Dow and Mitsubishi. The company just merged Veeral Additives, added 24,000 TPA antioxidant capacity, and commissioned fresh ATBS capacity. Management is guiding 15-20% revenue growth in FY26 and 20% CAGR over three years. The numbers are screaming. The stock is whispering.
Q3 FY26 was quarterly results — PAT up, OPM at 30.4%, ATBS expansion live, ₹570 Cr capex locked. The only thing missing is market attention. Time to put on the detective hat.
CARE Ratings (Oct 2025): CARE AA+; Stable / CARE A1+. Reaffirmed. Zero long-term debt, strong liquidity, market leadership intact. Nothing to see here except a company printing money with zero leverage.
03 — Business Model: WTF Do They Even Do?
They Make Molecules Nobody Else Can. At Scale. For Decades.
Vinati Organics is an Infrastructure Finance Company? No. It is the world’s largest manufacturer of Isobutyl Benzene (IBB) and 2-Acrylamido-2-Methylpropane Sulphonic Acid (ATBS) — 65% global share each. These are not “me-too” chemicals. Complex processes, high entry barriers, long qualification cycles. Think patent-like moats without the patents.
Portfolio: Specialty Aromatics (IBB, SBB, TBA), Specialty Monomers (ATBS, TBA), Butyl Phenols, Antioxidants (post-Veeral merger), Miscellaneous Polymers and Inorganic Chemicals. Backward integration in Isobutylene and Butyl Phenols keeps costs sticky. Two plants in Maharashtra. 55% exports, long-term contracts with global majors. Renewable energy now at 33 MW solar — 44% of power needs met green.
New growth engines: Veeral Organics (WOS) capex ₹500 Cr for MEHQ, Guaiacol, Isoamylene derivatives. ATBS expansion Phase-1 (10k TPA) already commercial from Nov 2025. Total FY26 capex guidance ₹570 Cr — all funded internally. No debt, no dilution, no drama.
IBB + ATBS49%of revenue FY24
Exports55%of revenue
Global Share65%IBB & ATBS
Renewable Power44%of consumption
Fun fact: Every time you buy a premium diaper, a water-treatment polymer or a certain hypertension drug, there is a decent chance Vinati’s molecule is inside. No Instagram reels. No Shark Tank pitch. Just 65% of the planet’s supply.
04 — Financials Overview
Q3 FY26: The Numbers Go Brrr (Quietly)
Result type: Quarterly Results | Q3 FY26 EPS: ₹10.46 | Avg Q1–Q3 EPS: (₹10.88 + ₹12.45 + ₹10.46)/3 = ₹11.26 | Annualised EPS: ₹45.05
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 529 | 522 | 546 | +1.34% | -3.11% |
| Operating Profit | 161 | 143 | 179 | +12.59% | -10.06% |
| OPM % | 30.4% | 27% | 33% | +340 bps | -260 bps |
| PAT | 108 | 96 | 129 | +12.50% | -16.28% |
| EPS (₹) | 10.46 | 9.22 | 12.45 | +13.45% | -16.00% |
P/E Check: TTM EPS = ₹46.10. CMP = ₹1,386. P/E = 30.1x. Industry median ~26.8x. Vinati trades at a 12% premium despite zero debt, 65% global share and cleanest balance sheet in specialty chemicals. The market is pricing in… what exactly? Execution risk on new capex? Or just forgetting how profitable this detective actually is?
💬 At 30.1x P/E with 65% global share and zero debt, what do you think is keeping the stock from re-rating? Merger hangover, new capex risk, or plain old market amnesia? Drop your thoughts in the comments.
05 — Valuation: Fair Value Range
What Is This Chemical Detective Actually Worth?
Join 10,000+ investors who read this every week.
